Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | RLMD |
---|---|---|
09:32 ET | 3420 | 3.31 |
09:41 ET | 100 | 3.34 |
09:43 ET | 1312 | 3.345 |
09:45 ET | 1288 | 3.37 |
09:48 ET | 100 | 3.48 |
09:50 ET | 100 | 3.46 |
09:52 ET | 100 | 3.46 |
09:54 ET | 2000 | 3.45 |
09:56 ET | 100 | 3.54 |
09:57 ET | 100 | 3.53 |
10:06 ET | 100 | 3.4766 |
10:08 ET | 1200 | 3.47 |
10:12 ET | 617 | 3.445 |
10:15 ET | 100 | 3.445 |
10:19 ET | 100 | 3.445 |
10:21 ET | 14747 | 3.37 |
10:24 ET | 100 | 3.374 |
10:26 ET | 12600 | 3.35 |
10:28 ET | 200 | 3.345 |
10:30 ET | 200 | 3.3699 |
10:32 ET | 200 | 3.345 |
10:33 ET | 100 | 3.34 |
10:39 ET | 100 | 3.345 |
10:42 ET | 200 | 3.345 |
10:48 ET | 100 | 3.35 |
10:51 ET | 100 | 3.34 |
10:53 ET | 100 | 3.359 |
10:55 ET | 2470 | 3.38 |
10:57 ET | 100 | 3.41 |
11:02 ET | 444 | 3.37 |
11:04 ET | 100 | 3.41 |
11:08 ET | 700 | 3.39 |
11:09 ET | 3990 | 3.34 |
11:11 ET | 15621 | 3.285 |
11:13 ET | 100 | 3.28 |
11:15 ET | 1600 | 3.21 |
11:18 ET | 300 | 3.21 |
11:20 ET | 100 | 3.23 |
11:22 ET | 3360 | 3.19 |
11:24 ET | 4955 | 3.25 |
11:27 ET | 488 | 3.255 |
11:29 ET | 2100 | 3.23 |
11:31 ET | 100 | 3.25 |
11:33 ET | 1100 | 3.22 |
11:36 ET | 800 | 3.2001 |
11:38 ET | 1173 | 3.195 |
11:40 ET | 667 | 3.19 |
11:42 ET | 100 | 3.17 |
11:44 ET | 3225 | 3.17 |
11:49 ET | 500 | 3.165 |
11:54 ET | 100 | 3.165 |
11:56 ET | 2400 | 3.13 |
11:58 ET | 1900 | 3.125 |
12:00 ET | 405 | 3.13 |
12:02 ET | 230 | 3.13 |
12:05 ET | 800 | 3.11 |
12:09 ET | 800 | 3.14 |
12:12 ET | 285 | 3.1333 |
12:14 ET | 100 | 3.14 |
12:16 ET | 200 | 3.13 |
12:18 ET | 3100 | 3.2 |
12:20 ET | 2000 | 3.2099 |
12:21 ET | 100 | 3.22 |
12:23 ET | 2000 | 3.2 |
12:27 ET | 100 | 3.22 |
12:32 ET | 100 | 3.205 |
12:34 ET | 100 | 3.2 |
12:36 ET | 200 | 3.205 |
12:38 ET | 400 | 3.205 |
12:39 ET | 100 | 3.22 |
12:45 ET | 200 | 3.205 |
12:48 ET | 200 | 3.21 |
12:50 ET | 200 | 3.18 |
12:52 ET | 200 | 3.18 |
12:54 ET | 3272 | 3.145 |
12:56 ET | 1200 | 3.145 |
12:57 ET | 200 | 3.145 |
12:59 ET | 300 | 3.145 |
01:01 ET | 700 | 3.135 |
01:06 ET | 628 | 3.14 |
01:08 ET | 200 | 3.11 |
01:10 ET | 300 | 3.11 |
01:12 ET | 300 | 3.11 |
01:14 ET | 100 | 3.11 |
01:15 ET | 550 | 3.11 |
01:17 ET | 100 | 3.1136 |
01:19 ET | 200 | 3.11 |
01:21 ET | 300 | 3.1 |
01:24 ET | 200 | 3.12 |
01:26 ET | 1200 | 3.11 |
01:32 ET | 644 | 3.11 |
01:33 ET | 741 | 3.11 |
01:35 ET | 3794 | 3.13 |
01:39 ET | 2300 | 3.135 |
01:46 ET | 100 | 3.12 |
01:50 ET | 100 | 3.135 |
01:53 ET | 300 | 3.135 |
01:55 ET | 400 | 3.15 |
01:57 ET | 827 | 3.15 |
02:00 ET | 800 | 3.15 |
02:09 ET | 100 | 3.15 |
02:11 ET | 432 | 3.16 |
02:18 ET | 5114 | 3.18 |
02:22 ET | 600 | 3.2 |
02:26 ET | 738 | 3.2 |
02:36 ET | 800 | 3.2 |
02:38 ET | 600 | 3.2 |
02:40 ET | 700 | 3.2 |
02:42 ET | 400 | 3.2 |
02:44 ET | 400 | 3.21 |
02:45 ET | 300 | 3.21 |
02:47 ET | 2303 | 3.21 |
02:49 ET | 300 | 3.21 |
02:51 ET | 300 | 3.21 |
02:54 ET | 100 | 3.21 |
02:56 ET | 400 | 3.21 |
03:00 ET | 1032 | 3.21 |
03:02 ET | 200 | 3.21 |
03:05 ET | 700 | 3.21 |
03:07 ET | 552 | 3.22 |
03:14 ET | 700 | 3.22 |
03:16 ET | 300 | 3.22 |
03:18 ET | 200 | 3.23 |
03:21 ET | 300 | 3.23 |
03:23 ET | 300 | 3.23 |
03:25 ET | 200 | 3.23 |
03:27 ET | 300 | 3.23 |
03:30 ET | 700 | 3.23 |
03:32 ET | 300 | 3.23 |
03:34 ET | 200 | 3.23 |
03:36 ET | 200 | 3.23 |
03:38 ET | 800 | 3.23 |
03:39 ET | 400 | 3.23 |
03:41 ET | 7290 | 3.23 |
03:43 ET | 2308 | 3.235 |
03:45 ET | 700 | 3.26 |
03:48 ET | 1200 | 3.27 |
03:52 ET | 1100 | 3.27 |
03:54 ET | 800 | 3.27 |
03:56 ET | 1864 | 3.27 |
03:57 ET | 1754 | 3.28 |
03:59 ET | 14454 | 3.24 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Relmada Therapeutics Inc | 97.8M | -1.1x | --- |
Leap Therapeutics Inc | 98.3M | -1.3x | --- |
Eledon Pharmaceuticals Inc | 98.7M | -1.0x | --- |
Tiziana Life Sciences Ltd | 99.0M | -5.6x | --- |
Benitec Biopharma Inc | 97.0M | -0.9x | --- |
Citius Oncology Inc | 99.1M | 5.7x | --- |
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Its esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $97.8M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 30.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.51 |
EPS | $-2.88 |
Book Value | $2.84 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.